ClinicalTrials.gov
ClinicalTrials.gov Menu

MRI Detection of Microbleeds in Glioma Patients (SWIGLI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02899663
Recruitment Status : Completed
First Posted : September 14, 2016
Last Update Posted : September 14, 2016
Sponsor:
Information provided by (Responsible Party):
Fondation Ophtalmologique Adolphe de Rothschild

Brief Summary:
Systematic retrospective medical chart and medical imaging file review of all patients receiving brain MRI for the follow-up of glioblastoma.

Condition or disease
Glioblastoma

Study Type : Observational
Actual Enrollment : 58 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Detection of Microbleeds With MRI (SWI Sequences) in Glioma Patients
Study Start Date : January 2015
Actual Primary Completion Date : August 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources




Primary Outcome Measures :
  1. Number of microbleeds diagnosed with MRI (susceptibility weighted imaging sequence) [ Time Frame: At the time of each MRI conducted within 5 years after diagnosis ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patients suffering from brain glioblastoma
Criteria

Inclusion Criteria:

  • Adult patients
  • Diagnosed with brain glioblastoma
  • Receiving treatment with cranial radiotherapy and/or chemotherapy
  • Having at least one follow-up MRI conducted that used a susceptibility weighted imaging sequence

Exclusion Criteria:

  • Underage
  • Absence of formal diagnosis of glioblastoma
  • No available medical imaging file with MRI susceptibility weighted imaging sequence

Responsible Party: Fondation Ophtalmologique Adolphe de Rothschild
ClinicalTrials.gov Identifier: NCT02899663     History of Changes
Other Study ID Numbers: NI_ALR_2016_1
First Posted: September 14, 2016    Key Record Dates
Last Update Posted: September 14, 2016
Last Verified: September 2016

Additional relevant MeSH terms:
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue